|View printer-friendly version|
"We are excited for the NV-02 program to advance into field studies. To our knowledge, this is the most advanced clinical study of a feline mAb therapy. We anticipate the data generated will be valuable in selecting the optimum dosing regimen for NV-02 and designing a future pivotal study," said Dr.
The study will be a placebo-controlled, blinded, pilot field safety and efficacy study targeting enrolment of 90 cats with naturally occurring osteoarthritis. The study will take place across 15 sites in
Currently, non-steroidal anti-inflammatory drugs (NSAIDs) are the leading class of analgesics in dogs and cats. In
Nexvet is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals, such as dogs and cats, by developing and commercializing novel, species-specific biologics. Nexvet's proprietary PETization™ platform is designed to rapidly design monoclonal antibodies ("mAbs") that are recognized as "self" or "native" by an animal's immune system, a property Nexvet refers to as "100% species-specificity." Nexvet's product candidates also build upon the safety and efficacy data from clinically tested human therapies, thereby reducing clinical risk and development cost.
Nexvet is leveraging diverse global expertise and incentives to build a vertically integrated biopharmaceutical company, through conducting drug discovery in
CONTACT: Further information: Investors
Candice Knoll Blueprint Life Science Group+1 415-375-3340 Ext. 4 firstname.lastname@example.org Media David SalisburyBerry & Company Public Relations +1 212-253-8881 email@example.com
Unit 5, Sragh Technology Park
Rahan Road, Tullamore
Co. Offaly, R35 FR98
P: + 353 5793 24522
Level 8, 31 Queen Street
P: +61 (3) 9610 4400
275 Post Street
San Francisco, CA 94108